88 related articles for article (PubMed ID: 14534923)
21. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
22. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
23. Myocardial distribution of (18)F-FDG and (99m)Tc-sestamibi on dual-isotope simultaneous acquisition SPET compared with PET.
Matsunari I; Kanayama S; Yoneyama T; Matsudaira M; Nakajima K; Taki J; Nekolla SG; Takekoshi N; Tonami N; Hisada K
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1357-64. PubMed ID: 12271419
[TBL] [Abstract][Full Text] [Related]
24. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.
Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC
Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax.
Demura Y; Tsuchida T; Ishizaki T; Mizuno S; Totani Y; Ameshima S; Miyamori I; Sasaki M; Yonekura Y
J Nucl Med; 2003 Apr; 44(4):540-8. PubMed ID: 12679397
[TBL] [Abstract][Full Text] [Related]
26. Unique myoclonic pattern in corticobasal degeneration.
Brunt ER; van Weerden TW; Pruim J; Lakke JW
Mov Disord; 1995 Mar; 10(2):132-42. PubMed ID: 7753055
[TBL] [Abstract][Full Text] [Related]
27. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer.
Higashi K; Nishikawa T; Seki H; Oguchi M; Nambu Y; Ueda Y; Yuasa K; Tonami H; Okimura T; Yamamoto I
J Nucl Med; 1998 Jan; 39(1):9-15. PubMed ID: 9443730
[TBL] [Abstract][Full Text] [Related]
28. Absolute quantification of regional cerebral glucose utilization in mice by 18F-FDG small animal PET scanning and 2-14C-DG autoradiography.
Toyama H; Ichise M; Liow JS; Modell KJ; Vines DC; Esaki T; Cook M; Seidel J; Sokoloff L; Green MV; Innis RB
J Nucl Med; 2004 Aug; 45(8):1398-405. PubMed ID: 15299067
[TBL] [Abstract][Full Text] [Related]
29. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis.
Tatsumi M; Cohade C; Nakamoto Y; Wahl RL
Radiology; 2003 Dec; 229(3):831-7. PubMed ID: 14593193
[TBL] [Abstract][Full Text] [Related]
30. Influence of mild hyperglycemia on cerebral FDG distribution patterns calculated by statistical parametric mapping.
Kawasaki K; Ishii K; Saito Y; Oda K; Kimura Y; Ishiwata K
Ann Nucl Med; 2008 Apr; 22(3):191-200. PubMed ID: 18498034
[TBL] [Abstract][Full Text] [Related]
31. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies.
Pirotte B; Goldman S; Massager N; David P; Wikler D; Lipszyc M; Salmon I; Brotchi J; Levivier M
J Neurosurg; 2004 Sep; 101(3):476-83. PubMed ID: 15352606
[TBL] [Abstract][Full Text] [Related]
32. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
33. Paraneoplastic syndromes: detection of malignant tumors using [(18)F]FDG-PET.
Berner U; Menzel C; Rinne D; Kriener S; Hamscho N; Döbert N; Diehl M; Kaufmann R; Grünwald F
Q J Nucl Med; 2003 Jun; 47(2):85-9. PubMed ID: 12865868
[TBL] [Abstract][Full Text] [Related]
34. Clinical value of [(18)F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin.
Blockmans D; Knockaert D; Maes A; De Caestecker J; Stroobants S; Bobbaers H; Mortelmans L
Clin Infect Dis; 2001 Jan; 32(2):191-6. PubMed ID: 11170907
[TBL] [Abstract][Full Text] [Related]
35. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
36. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
[TBL] [Abstract][Full Text] [Related]
37. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
Tsukamoto N; Kojima M; Hasegawa M; Oriuchi N; Matsushima T; Yokohama A; Saitoh T; Handa H; Endo K; Murakami H
Cancer; 2007 Aug; 110(3):652-9. PubMed ID: 17582800
[TBL] [Abstract][Full Text] [Related]
38. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET.
Yun M; Choi HS; Yoo E; Bong JK; Ryu YH; Lee JD
J Nucl Med; 2005 Jun; 46(6):953-7. PubMed ID: 15937305
[TBL] [Abstract][Full Text] [Related]
39. Differential diagnosis of thymic tumors using a combination of 11C-methionine PET and FDG PET.
Sasaki M; Kuwabara Y; Ichiya Y; Akashi Y; Yoshida T; Nakagawa M; Murayama S; Masuda K
J Nucl Med; 1999 Oct; 40(10):1595-601. PubMed ID: 10520697
[TBL] [Abstract][Full Text] [Related]
40. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer.
Zimny M; Siggelkow W; Schröder W; Nowak B; Biemann S; Rath W; Buell U
Gynecol Oncol; 2001 Nov; 83(2):310-5. PubMed ID: 11606090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
